Schering-Plough wins an EC approval

Schering-Plough says the EC has approved Bridion (sugammadex) injection, "the first and only selective relaxant binding agent and the first major pharmaceutical advance in the field of anesthesia in two decades." Release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.